2026 Interim Report
Filed with HKEX · Stock code 2487 · · 61 pages · English
Summary by 6ix AI
The report highlights the commercialization of key products, including topical treatments for scalp and skin diseases, which have begun to gain market acceptance. It also discusses the company's revenue, which has seen a slight decrease due to the termination of certain distribution agreements. The report outlines future development plans aimed at enhancing market penetration and expanding the product portfolio.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Cutia Therapeutics
- Voluntary announcement - CU-40102 (topical finasteride spray) obtained marketing approval by the macao pharmaceutical administration bureau
- Poll results of the annual general meeting held on 26 June 2026
Later from Cutia Therapeutics
- Change of executive director
- List of directors and their roles and functions
- Voluntary announcement - share repurchase program under the share repurchase mandate
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
Follow Cutia Therapeutics into a list and get an email when it puts out news.
Follow Cutia Therapeutics